Smaller primary tumor size was also more prone to achieving response in the total study population; however, difference was close to being significant ( P value 0.065).
← all excerpts
Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.
1
—
—